Skip to main
LUNG
LUNG logo

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 0%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx Corp is positioned for a positive financial outlook due to expected revenue acceleration in 2026 and beyond, supported by strong international momentum despite temporary challenges in China. The company is focused on disciplined investment, reaffirming a gross margin guidance of 74% for 2025 while tightening operating expense expectations to $128 million–$130 million. Additionally, the successful execution of their AeriSeal convert trial and the integration of AI-driven tools like LungTraX Detect will be crucial for expanding global access and enhancing patient identification, ultimately driving sustained adoption of their products.

Bears say

Pulmonx Corp faces a challenging financial landscape due to its reliance on a limited product range that may hinder revenue diversification, primarily generated through sales of its Zephyr Endobronchial Valve and related systems. Additionally, the company has experienced sluggish growth in key markets, particularly in the U.S., where competitive pressures and product adoption rates pose significant risks to its financial stability. Furthermore, ongoing operational costs and potential regulatory hurdles could impact profitability and overall market performance, contributing to a negative outlook on the company’s stock.

Pulmonx (LUNG) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 0% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 7 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.66, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.66, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.